LPL Financial LLC Has $4.21 Million Stock Position in Repligen Corporation $RGEN

Key Points

• LPL Financial LLC increased its stake in Repligen Corporation by 6.7% in the first quarter, now holding 34,405 shares valued at approximately $4.2 million.
• Repligen reported a 14.8% year-over-year revenue increase in its latest quarterly earnings, reaching $182.37 million, although it missed analysts' EPS estimates.
• Major investment firms have adjusted their target prices for Repligen stocks, with a consensus rating of "Moderate Buy" and an average price target of $169.45.

LPL Financial LLC boosted its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 6.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,405 shares of the biotechnology company's stock after purchasing an additional 2,168 shares during the period. LPL Financial LLC owned 0.06% of Repligen worth $4,212,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. TD Asset Management Inc increased its holdings in shares of Repligen by 10.9% in the first quarter. TD Asset Management Inc now owns 51,172 shares of the biotechnology company's stock valued at $6,511,000 after purchasing an additional 5,014 shares in the last quarter. Drive Wealth Management LLC acquired a new stake in shares of Repligen in the 1st quarter valued at $471,000. Neo Ivy Capital Management bought a new stake in shares of Repligen during the first quarter worth $2,091,000. Legato Capital Management LLC lifted its stake in shares of Repligen by 101.5% during the first quarter. Legato Capital Management LLC now owns 16,000 shares of the biotechnology company's stock valued at $2,036,000 after acquiring an additional 8,060 shares during the period. Finally, Crestwood Advisors Group LLC bought a new position in Repligen in the first quarter valued at about $464,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Barclays assumed coverage on Repligen in a report on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price objective for the company. JPMorgan Chase & Co. lowered their target price on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Royal Bank Of Canada raised their price target on Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 30th. Wall Street Zen downgraded Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Finally, Evercore ISI cut their target price on Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $169.45.

Insider Activity

In related news, Director Martin D. Madaus acquired 1,800 shares of the company's stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the acquisition, the director directly owned 1,800 shares in the company, valued at approximately $201,834. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Repligen Stock Up 0.4%

Shares of NASDAQ RGEN traded up $0.54 during mid-day trading on Tuesday, reaching $124.62. 60,224 shares of the company's stock were exchanged, compared to its average volume of 776,558. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $7.01 billion, a price-to-earnings ratio of -500.27, a PEG ratio of 2.29 and a beta of 1.05. The business has a fifty day simple moving average of $122.35 and a 200 day simple moving average of $132.20.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%. The business had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same period in the previous year, the company posted $0.40 earnings per share. Repligen's revenue for the quarter was up 14.8% compared to the same quarter last year. As a group, equities analysts expect that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.